BioPharma affiliate ABVC records a total of US$1.03 million in licensing earnings from Q3 up until now, showcasing their profitable business strategy.
In a recent development, ABVC BioPharma, Inc. has announced the receipt of additional licensing revenues from OncoX BioPharma, Inc. This latest payment brings ABVC's total Q3 2025 licensing revenues from OncoX to US$595,950.
This revenue addition strengthens ABVC's cash position and profitability profile, as it represents a high-margin stream with minimal incremental operating costs. The total consolidated licensing revenues for ABVC from all strategic partners in Q3 2025 amounted to US$1,275,950.
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. It operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility.
The partnership between ABVC and OncoX is far from over. OncoX is projected to reach a global market size of $187 million by 2030 in cross-sector applications. ABVC BioPharma intends to conduct pivotal clinical trials (Phase III) for Vitargus®, its medical device under development, through global partnerships.
It's important to note that ABVC's forward-looking statements are subject to various risks and uncertainties, including difficulties in manufacturing product candidates, financing, competition, key executive losses, and regulatory approval issues. More detailed information about these risks can be found in ABVC BioPharma's filings with the Securities and Exchange Commission (SEC).
ABVC BioPharma utilizes in-licensed technology from world-renowned research institutions like Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. The contact for ABVC BioPharma is Uttam Patil at [email protected].
OncoX, on the other hand, is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. Its current pipeline includes three proprietary pipeline programs, including a lead product candidate targeting solid tumors and hematologic malignancies.
The original press release can be viewed on www.newmediawire.com. This press release does not constitute an offer to sell or buy any of the company's securities without registration or an applicable exemption.
Read also:
- Catastrophe at a U.S. Steel facility in Pennsylvania results in the loss of two lives. crucial details unveiled
- Manipulating Sympathy: Exploiting Victimhood for Personal Gain
- Prices remain a concern for the Germans
- Auto Industry Updates: Geotab, C2A, Deloitte, NOVOSENSE, Soracom, and Panasonic in Focus
